At a glance
- Originator Nonindustrial source
- Developer BTG
- Class Antidementias; Antidepressants; Neuroprotectants
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Alzheimer's disease; Major depressive disorder
Most Recent Events
- 19 Aug 2019 BTG has been acquired by Boston Scientific Corporation
- 28 Sep 2001 No-Development-Reported for Alzheimer's disease in United Kingdom (Unknown route)
- 28 Sep 2001 No-Development-Reported for Depression in United Kingdom (Unknown route)